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Imatinib, an inhibitor of PDGF-Rb and other tyrosine kinase receptors, has been shown to decrease microvessel density and
interstitial fluid pressure in solid tumours, thereby improving subsequent delivery of small molecules. The purpose of this study was to
test whether pretreatment with imatinib increases the efficacy of traditional chemotherapy in mice bearing non-small cell lung
carcinoma xenografts, and to investigate the effects of imatinib on liposomal drug delivery. Efficacy treatment groups included (n¼9–
10): saline control, imatinib alone (oral gavage, 100mgkg
 1 7 days), docetaxel alone (10mgkg
 1 i.p. 2 /week until killing), and
imatinib plus docetaxel (started on day 7 of imatinib). Tumours were monitored until they reached four times the initial treatment
volume (4 V) or 28 days. A separate experiment compared tumour doxorubicin concentrations (using high performance liquid
chromatography) 24h after treatment with liposomal doxorubicin alone (6mgkg
 1 i.v., n¼9) or imatinib plus liposomal doxorubicin
(n¼16). Imatinib plus docetaxel resulted in significantly improved antitumour efficacy (0/10 animals reached 4 V by 28 days) when
compared to docetaxel alone (3/9 reached 4 V, P¼0.014) or imatinib alone (9/10 reached 4 V, P¼0.025). Pretreatment with
imatinib also significantly increased tumour concentrations of liposomal doxorubicin. Overall, these preclinical studies emphasise the
potential of imatinib as an adjunct to small molecule or liposomal chemotherapy.
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Non-small cell lung carcinoma (NSCLC) has a limited response
rate to current chemotherapeutics, with tumour shrinkage in only
20% of patients (by the RECIST criteria) and 2-year survival rates
of 10–16% (Schiller et al, 2002). One of the major barriers to
effective chemotherapy is the lack of adequate drug delivery to
lung tumours, which has been linked to high tumour interstitial
fluid pressures (IFPs) of up to 25mm Hg (Jain, 1996). This
challenge has also been demonstrated for many other solid
tumours, including breast carcinoma, head and neck carcinoma,
and melanoma (Jain, 1996; Heldin et al, 2004). Loss of pressure
gradient across the microvessel wall inhibits drug transport from
blood to the interstitium. In fact, elevated pressure throughout the
core of solid tumours often results in drug distribution only to the
periphery of tumours after intravenous injection (Boucher et al,
1990; Viglianti et al, 2004). Therefore, the rationale is quite strong
for developing a method to improve tumour drug delivery by
reducing IFP (Heldin et al, 2004; Jain, 2005).
Systemic chemotherapeutics encounter a number of obstacles
that limit transport to solid tumours (Jain, 2001; Truskey et al,
2004). First, tumour angiogenesis results in immature vasculature
with abnormal architecture and leaky, heterogeneous vessel walls
(Yuan et al, 1995; Yuan, 1998). Vessels may also be compressed by
the solid stress of proliferating tumour parenchyma and stroma
(Boucher and Jain, 1992; Griffon-Etienne et al, 1999). These factors
are known to impair vascular perfusion, thereby limiting drug
access to the tumour. As noted above, another major problem is
interstitial hypertension, which decreases convective transport of
drug across the microvessel wall (Boucher et al, 1990; Heldin
et al, 2004). Elevated IFP has been attributed to leakage of plasma
proteins and fluid from permeable tumour vessels with high
intravascular pressure. Tumours lack functional lymphatics to
remove the excess interstitial fluid, and pressure equilibrates
across the wall (Boucher and Jain, 1992). Furthermore, fibroblasts
and pericytes have been shown to contribute to elevated IFP by
exerting PDGF-mediated tension on the interstitial collagen matrix
(Heldin et al, 2004). The PDGF receptors, located on stroma and
perivascular cells, dimerise and bind PI3K, leading to integrin-
mediated action on collagen fibers (Heuchel et al, 1999; Pietras
et al, 2001).
Non-small cell lung carcinoma exhibits high IFP, upregulated
PDGF, and a poor clinical prognosis, making this a particularly
valuable model for impaired drug delivery (Kawai et al, 1997;
Vlahovic et al, 2006). Interstitial hypertension particularly affects
macromolecular therapies such as liposomes, antibodies, and
proteins, as they require convective transport to cross the
capillary wall (Jain and Baxter, 1988; Yuan, 1998; Netti et al,
1999). The current strategies for reducing IFP include blockage of
cytokines (e.g. VEGF, PDGF, and TGF-b) and decompression of
vessels by induction of tumour cell death (Boucher and Jain, 1992;
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sGriffon-Etienne et al, 1999). Blocking VEGF prunes immature
vessels, increases fraction of pericyte-covered vessels, and
decreases vessel permeability, dilation and tortuosity (Tong et al,
2004; Willett et al, 2004; Jain, 2005). Inhibition of PDGF or PDGF-
Rb also prunes immature vessels, and additionally decreases
contraction of the interstitial space and proliferation of stroma
(Heuchel et al, 1999; Pietras et al, 2001; George, 2003; Matei et al,
2004; Vlahovic et al, 2006).
Imatinib (Gleevec, Novartis Pharmaceuticals Corp., East
Hanover, NJ, USA) is a synthetic small molecule that inhibits
phosphorylation of a number of tyrosine kinase receptors
including PDGFR, c-kit, and bcr-abl (Buchdunger et al, 1995;
George, 2003; Matei et al, 2004). It decreases proliferation of both
tumour and stromal cells (George, 2003; Furuhashi et al, 2004; Kim
et al, 2004; Matei et al, 2004; Ostman, 2004). In colonic xenografts,
Pietras et al (2001) demonstrated that imatinib decreases IFP and
thereby increases transcapillary transport of small molecules.
We have recently reported the effects of imatinib on NSCLC
xenografts, showing that 4 days of therapy (50mgkg
 1 gavage)
significantly decreases IFP and microvascular density, lowers
VEGF levels, and improves tumour oxygen delivery (Vlahovic et al,
2006). In the current study, we have continued this work by
investigating whether pretreatment with imatinib can be used to
affect tumour vasculature and consequently improve the efficacy
of traditional chemotherapeutics in NSCLC xenografts. Further-
more, we provide a proof of principle for the use of imatinib to
improve liposomal drug delivery in this model.
MATERIALS AND METHODS
Materials
Imatinib (Gleevec, STI571, Novartis Pharmaceuticals Corp.) was
obtained from the hospital pharmacy in a 100-mg tablet form.
Tablets were crushed and re-suspended in 0.9% NaCl. Liposomal
doxorubicin (Doxil) was obtained from Ortho Biotech Products
(Bridgewater, NJ, USA), and docetaxel (Taxotere) was obtained
from Sanofi Aventis (Bridgewater). A human NSCLC line, A549,
was purchased from American Type Culture Collection (Manassas,
VA, USA).
Non-small cell lung carcinoma xenograft model
Homozygous adult female athymic nude mice were housed in
isolated caging with sterile rodent food and water ad libitum.
Human NSCLC cells (A549) were grown in RPMI 1640 media
supplemented with 5% bovine calf serum. The right hind limb of
each mouse was inoculated subcutaneously with B5.0 10
5 A549
cells, obtained from exponentially growing cell cultures, suspended
in 200ml of HEPES-buffered saline. Xenograft tumour growth was
monitored twice per week until tumours reached an average
volume of 100mm
3. Xenograft volume (V) was determined by the
following equation: V¼(L W
2) 0.5, where L is the length and
W is the width of the flank tumour.
Therapy and tumour harvest
After xenografts reached treatment volume (100mm
3), tumour-
bearing animals were used in three separate studies. The first study
compared vascular maturity (by immunohistochemistry) after
treatment with imatinib (n¼4) vs control (saline, n¼5). Imatinib
was administered via gavage once a day at a dose of 100mgkg
 1
for 7 days, and saline was administered following the same
schedule. Animals were killed 24h after the last imatinib injection,
and tumours were harvested and snap frozen at  801C.
The second study compared tumour growth times after
treatment with control (saline plus saline), imatinib alone (plus
saline), docetaxel alone (plus saline), or imatinib plus docetaxel
(n¼9–10 mice per group). Docetaxel was administered intraper-
itoneally at a dose of 10mgkg
 1 twice per week until killing, and
saline was administered following the same schedule. Injections of
docetaxel (docetaxel7imatinib groups) or intraperitoneal saline
(controlþimatinib alone groups) were initiated on day 7 of
imatinib or saline pretreatment. After therapy, animals were
monitored as they recovered from anaesthesia. Tumour volumes
were measured three times per week for 28 days or until the
tumour volume reached four times the volume on the first day of
treatment.
The third study compared tumour doxorubicin concentrations
after treatment with liposomal doxorubicin alone (n¼9) vs
imatinib plus liposomal doxorubicin (n¼16, randomised in 1:2
ratio). Liposomal doxorubicin was delivered intravenously as a
single dose (6mgkg
 1). When combined with imatinib, liposomal
doxorubicin was delivered on day 7 of imatinib treatment. Animals
were killed 1 day (24h) after liposomal doxorubicin injection,
and tumours were harvested and snap frozen at  801C. All animal
protocols were approved by the Duke University Animal Care and
Use Committee. Experiments were performed in accordance
with the Interdisciplinary Principles and Guidelines for the Use
of Animals in Research, Marketing, and Education (New York
Academy of Sciences, New York, NY, USA), as well as the UKCCCR
guidelines (Anon, 1988).
Immunohistochemical staining
Vascular markers for this study included the endothelial cell
markers CD31 and CD105, as well as smooth muscle alpha-actin
(a-SMA). CD31 was used to stain all endothelial cells, whereas
CD105 was used to indicate immature endothelial cells. Smooth
muscle a-actin was used to stain pericytes covering microvessels.
Frozen tumours harvested from control and imatinib alone groups
were cut into 10–12mm sections using a LEICA CM 1850 cryotome
(Meyer Instruments Inc., Houston, TX, USA). Consecutive tissue
sections were cut at the largest circumference of the tumour
and placed onto poly-L-lysine-coated slides (Polysciences Inc.,
Warrington, PA, USA). Cryosections were then split into two sets
for staining. All antibodies were diluted in phosphate-buffered
saline (PBS) with 0.1% bovine serum albumin and 0.1% Tween-20
(PBS-BT).
In the first set, sections were stained for CD31 and a-SMA.
Cryosections were air dried and fixed for 10min in acetone at 41C.
Tumour sections were then blocked with 10% normal donkey
serum for 15min and rinsed three times for 2min in PBS. Sections
were probed sequentially with primary antibodies against CD-31
(rat anti-mouse, diluted 1:100, BD Pharmingen, BD Biosciences,
San Jose, CA, USA) and a-SMA (mouse monoclonal antibody,
clone IA4, diluted 1:400, Lab Vision Corp., Fremont, CA, USA).
After rinsing again with PBS, primary antibodies were respectively
revealed with secondary antibodies coupled to TRITC (red, for
CD-31) or FITC (green, for a-SMA) (Jackson Immunoresearch,
West Grove, PA, USA).
In the second set, sections were stained for CD31 and CD105.
Sections were fixed for 1h in 4% paraformaldehyde in PBS (pH
7.2). Endogenous peroxidase activity was quenched with 3%
hydrogen peroxide for 15min, and tumour sections were then
blocked with 10% normal donkey serum for 15min and rinsed
three times for 2min in PBS. Consecutive sections were incubated
overnight at 41C with rat monoclonal antibody to CD31 diluted
1:200 or CD105 diluted 1:400 (BD Biosciences, San Jose, CA,
USA). After rinsing again with PBS, primary antibodies were
enhanced with biotinylated donkey anti-rat secondary antibody
(diluted 1:100) for 30min at room temperature (Jackson
Immunoresearch). Finally, an avidin-biotin complex was applied
(Vectastain ABC kit, Vector Lab Inc., Burlingame, CA, USA).
Markers were visualised with 3,30-diaminobenzidine tetrahydro-
chloride (DAB chromogen, Vector Lab Inc.).
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sImage analysis
Tumour sections were quantitatively analysed using a semiauto-
matic computerised digital image analysis system (Metamorph
Imaging System, Molecular Devices Corp, Sunnyvale CA, USA). A
high-resolution intensified solid-state camera was mounted on a
fluorescence microscope (Axioskop, Zeiss, Axioskop Zplus, Carl
Zeiss Inc., Germany) with a computer-controlled motorised
stepping stage. For the first set (CD31 vs a-SMA), digitised images
were acquired with both TRITC and FITC filters, and images were
overlaid using the Metamorph software. Microvessel density was
determined by counting CD31-positive structures in five random
fields per tumour, and a-SMA-positive vessels were counted from
among these structures.
For the second set (CD31 vs CD105), quantification of vessels
was performed using the Image J ‘Analyze Particles’ function by a
blind observer without any manipulation in brightness or contrast.
The threshold intensity was manually set above the background
staining intensity, and the Image J function selected for stained
vessels with a minimum size of 10 pixels per vessel. The average
number of CD31-stained vessels per region of interest (over three
regions per animal) was calculated as the microvessel density. The
average number of CD105-stained vessels in the same regions was
calculated from the consecutive section.
High performance liquid chromatography for doxorubicin
concentration
Tumours harvested from the liposomal doxorubicin group and the
imatinib plus liposomal doxorubicin group were cryo-crushed at
 801C, thawed, diluted, and homogenised. Three samples were
analysed from each tumour. Doxorubicin was extracted from
the homogenate using chloroform and silver nitrate. The organic
phase was separated, dried, and reconstituted in isopropanol.
Doxorubicin concentration was then measured by high
performance liquid chromatography (HPLC) with fluorimetry
(Cummings, 1985; Kong et al, 2000). A standard concentration set
was prepared using tumour homogenate and known concentra-
tions of doxorubicin. To correct error in weight measurement
due to variable tissue water content, concentrations were normal-
ised by total water-soluble protein concentration, which was
measured by the Bradford assay (colorimetric response of
Coomassie Blue G dye).
Statistical methods
Descriptive summary statistics are presented as mean7s.e. of the
mean, except for the time-to-four-times-tumour-volume data,
which are expressed as median values with 95% confidence
intervals. Statistical analyses of doxorubicin concentration and
histologic data were performed using the two-sample Student’s
t-test. For the antitumour efficacy data, the primary end point
(time to reach four times the original tumour volume) was
analysed using the Cox proportional hazards model to compare
groups. Censoring was taken into account for animals that did not
reach four times the original treatment volume by the time they
were killed (at 28 days). P-values less than 0.05 were considered to
be statistically significant.
RESULTS
Since imatinib is known to inhibit PDGF-Rb and decrease IFP in
solid tumours, it has the potential to ‘normalise’ the tumour
microenvironment and thereby improve delivery and efficacy of
chemotherapeutic agents. With this rationale, we performed three
in vivo translational studies on the effects of imatinib in NSCLC
xenografts. We first used histology to test the vascular effects
of imatinib, specifically assessing microvessel density (CD31
positivity), pericyte coverage (a-SMA positivity), and endothelial
cell immaturity (CD105 positivity). Then, we followed up on
recently published data that demonstrate that pretreatment with
imatinib increases delivery of small molecules to tumours (Pietras
et al, 2001; Vlahovic et al, 2006). We evaluated the antitumour
efficacy of imatinib plus docetaxel (a small molecule chemother-
apeutic commonly used for NSCLC treatment) in comparison with
either agent alone. Finally, as elevated IFP is known to be a major
barrier to convective transport of liposomes, we tested whether
pretreatment with imatinib can be used to increase tumour delivery
of liposomal doxorubicin. These three studies were designed to
complement previously published data and increase the under-
standing of PDGFRb-mediated effects of imatinib in NSCLC.
Representative images of NSCLC microvessels stained for CD31
(red) and a-SMA (green) are shown in Figure 1 after treatment
with saline (control) or imatinib. Pericytes (green) can be seen
overlying the endothelial cells (red), especially in larger vessels.
After a 7-day course of imatinib treatment, the total number of
vessels (anti-CD31-stained) decreased significantly from 51.074.7
to 29.573.2 (s.e., P¼0.01, Figure 2A). The number of anti-a-SMA-
stained microvessels, representing mature pericyte-covered
vessels, also decreased significantly, from 14.171.2 to 7.171.3
(P¼0.02). The percentage of total vessels that were positive for a-
SMA lowered from 28 to 23% (Figure 2A), indicating a trend
towards decreased pericyte coverage after treatment with imatinib
(not significantly different).
In a separate set of tumour sections, the average numbers of
CD31-stained and CD105-stained vessels were compared in
consecutive sections (Figure 2B). Owing to different image analysis
Red=CD31
Green=α-SMA
Control Imatinib
Figure 1 Representative fluorescent images of NSCLC xenograft sections after treatment with saline control or imatinib, 100mgkg
 1 7 days. Images
show endothelial cells stained with CD31 (red) and pericytes stained with anti-a-SMA (green).
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smethods, the absolute number of CD31-stained vessels in this
experiment (Figure 2B) was lower than in the former experiment
(Figure 2A), but treatment with imatinib again resulted in a
significant decrease in vessel density (P¼0.05). The density of
immature CD105-stained endothelial cells in the tumour decreased
from 19.572.5 to 8.772.0 after treatment with imatinib (P¼0.01),
and the ratio of CD105- to CD31-stained (total) vessels was used as
an indicator of vascular immaturity. This ratio was 0.9570.09 in
the control tumour and 0.8570.21 after imatinib therapy
(Figure 2B), showing a trend towards decreasing vessel immaturity
(or increasing maturity).
Figure 3 clearly shows that the combination of imatinib plus
docetaxel was significantly more effective than either agent alone
in the NSCLC xenograft. When docetaxel was administered after 7
days of imatinib treatment, tumour growth was delayed such that
no animals reached the end point of four times the original tumour
volume (4 V) by 28 days after therapy. In comparison, three out
of nine animals receiving docetaxel alone reached 4 V by 28
days, showing a significantly higher likelihood ratio for reaching
4 V (P¼0.014 vs combination). Almost all (9 out of 10) animals
receiving imatinib alone reached this end point, with a median
tumour growth time of 22.573.0 days (95% CI). Again, imatinib
alone showed a significantly higher likelihood ratio for reaching
4 V (P¼0.025 vs combination).
The assessment of imatinib plus liposomal doxorubicin showed
that prior treatment with imatinib improves delivery of liposomal
doxorubicin to NSCLC tumours (Figure 4). A single dose of
6mgkg
 1 liposomal doxorubicin (without imatinib) resulted in a
mean tumour doxorubicin concentration of 530.4753.5ng doxo-
rubicin per mg protein at 24h after injection (n¼9). Pretreatment
with 7 days of 100mgkg
 1 imatinib gavage significantly increased
the tumour doxorubicin concentration to 779.2768.8ng doxor-
ubicin per mg protein (n¼16, P¼0.02).
DISCUSSION
Imatinib has been implicated as a possible effector of vascular
‘normalisation’, the therapeutic paradigm proposed by Jain (2005)
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Figure 2 Vascular markers in NSCLC xenografts after treatment with saline control or imatinib, 100mgkg
 1 7 days. (A) The total numbers of anti-
CD31- and anti-a-SMA-stained vessels were measured in five regions of the same tumour section. The number of anti-CD31-stained vessels represents
total microvessel density, and the number of anti-a-SMA-stained vessels indicates the extent of pericyte coverage. Data represent mean7s.e. (B) The
average numbers of anti-CD31- and anti-CD105-stained vessels were measured in three regions of consecutive tumour sections. The number of anti-
CD105-stained vessels indicates relative endothelial cell immaturity. The number of anti-CD31-stained vessels differs from (A) due to distinct methods.
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Figure 3 Antitumour response in NSCLC xenografts after treatment
with saline, imatinib alone, docetaxel alone, or imatinib plus docetaxel
(n¼9–10 mice per group). Imatinib dose was 100mgkg
 1 oral gavage 7
days. Docetaxel dose was 10mgkg
 1 i.p. twice per week, starting on day 7
of imatinib or saline treatment. Tumours were monitored three times per
week until they reached four times the initial treatment volume (4 V)o r
28 days. The Kaplan–Meier plot represents the percentage of animals with
tumour volumes less than four times the volume at the beginning of
treatment, as a function of time after treatment.
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sto improve drug and oxygen delivery to tumours. Indeed, in
preclinical studies, imatinib therapy has normalised the tumour
microenvironment by decreasing IFP, increasing transcapillary
transport of oxygen and
51Cr-EDTA, and lowering VEGF and
microvessel density (Pietras et al, 2001; Vlahovic et al, 2006). The
current study further demonstrates a significant decrease in
density of immature endothelial cells (CD105þ), with a trend
towards higher endothelial cell maturity (lower CD105–CD31
ratio, Figure 2B). In addition, Figure 2A supports a trend towards
decreased fraction of pericyte coverage after imatinib therapy.
Although not a ‘normalising’ effect, this result is consistent with
imatinib inhibiting the actions of PDGF and PDGF-Rb in pericyte
recruitment and vessel wall stabilisation (George and Kaelin, 2003;
Ostman, 2004). Importantly, dosing and scheduling may be crucial
if ‘normalisation’ is the goal (Winkler et al, 2004; Jain, 2005).
Future studies should determine the temporal windows of IFP
reduction and vascular remodelling induced by imatinib in order
to optimise combined therapy schedules (Jain, 2005).
This is the first study to demonstrate the in vivo efficacy of
imatinib, as an adjunct to chemotherapy in NSCLC treatment. For
NSCLC, the most commonly used first line chemotherapeutics
include platinum, taxanes, gemcitabine, and vinorelbine (Schiller
et al, 2002). The taxane docetaxel was chosen for this preclinical
study, because it is FDA approved as a second line single-agent
therapy, and it is under clinical investigation as a first-line single-
agent therapy. Here we show that imatinib plus docetaxel resulted
in significantly improved antitumour efficacy when compared to
docetaxel alone or imatinib alone. These results, along with
previously published studies (Pietras et al, 2001; Vlahovic et al,
2006), suggest that imatinib improves small molecule drug
delivery, which is typically thought to be governed by diffusion
(Heldin et al, 2004). This may be linked to an increase in diffusion
by an unknown mechanism, possibly related to vessel remodelling
or available volume fraction in the extracellular matrix (Heuchel
et al, 1999; Ostman, 2004). However, some evidence suggests that
the effects of convection on small molecules may be under-
estimated, especially in the tumour microenvironment (Pietras
et al, 2001; Heldin et al, 2004; Ostman, 2004). Further preclinical
studies should investigate the drug delivery effects of this type of
combination therapy, and expand application to other tumour
models and other chemotherapeutic agents.
This study also provides a proof of principle for the enhance-
ment of liposomal (i.e. macromolecular) drug delivery by
reduction of IFP (Yuan et al, 1994, 1995). Macromolecular
transport is dominated by convection, which is governed by
hydrostatic and oncotic pressures (Starling forces) (Truskey et al,
2004). A decrease in interstitial hydrostatic pressure is expected to
increase the transport of macromolecules across the vessel wall
(Heldin et al, 2004). Thus, the observed increase in liposomal
doxorubicin delivery to NSCLC after pretreatment with imatinib
can be explained by the decrease in IFP previously reported by this
group in NSCLC (Figure 4, Pietras et al, 2001; Vlahovic et al, 2006).
Overall, the observed effects of imatinib in NSCLC are consistent
with the inhibition of PDGFR-b; these changes in the microenvi-
ronment, including decreased IFP and modified vasculature, result
in improved drug delivery and efficacy in the preclinical setting.
Currently, this hypothesis is being further tested in clinical trials in
which patients with metastatic NSCLC are treated with standard
cisplatin and docetaxel plus concurrent imatinib. All enrolled
patients must be PDGFR-b positive by immunohistochemistry,
and treatment response is monitored by the RECIST criteria.
Patients also participate in a lead-in portion of the study in which
dynamic contrast-enhanced (DCE) MRI is performed before and
after a 7-day course of imatinib alone, to explore DCE-MRI as a
biomarker for changes in the tumour microenvironment. Pre-
liminary data have revealed that DCE-MRI is feasible and
demonstrates a decrease in tumour leakage space (interstitial or
extracellular extravascular space) after treatment with imatinib.
This suggests a decrease in IFP that may imply improvement in
tumour drug delivery. However, a major challenge to clinical
research in drug delivery is the lack of non-invasive drug imaging
methods (Viglianti et al, 2004; Ponce et al, 2007). The phase I
portion of the clinical trial is completed, and the phase II portion
evaluating the efficacy of combined imatinib plus chemotherapy
is currently successfully enrolling. In conclusion, our preclinical
studies with imatinib in NSCLC demonstrate its potential to
improve tumour drug delivery and efficacy, and this strategy was
subsequently rapidly translated into clinical trials.
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protein) 24h after therapy with liposomal doxorubicin alone or imatinib
plus liposomal doxorubicin. Liposomal doxorubicin was administered i.v. at
a dose of 6mgkg
 1. For combined therapy, liposomes were administered
on day 7 of imatinib treatment (100mgkg
 1 oral gavage 7 days). Tumour
doxorubicin concentration was measured by HPLC, and data represent
mean7s.e.
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